Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer

Purpose To determine the frequency and association with relapse-free survival (RFS) of MET and PIK3CA copy number elevations in early stage breast cancer.

[1]  G. Mills,et al.  PI3K pathway-directed therapeutic strategies in cancer. , 2010, Current opinion in investigational drugs.

[2]  Mitsutaka Kadota,et al.  Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. , 2009, Cancer research.

[3]  P. Pandolfi,et al.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.

[4]  G. Mills,et al.  Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.

[5]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. V. Vande Woude,et al.  Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer , 2009, Clinical Cancer Research.

[7]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[8]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[9]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[10]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[11]  E. Tok,et al.  Expression of the c‐Met in advanced epithelial ovarian cancer and its prognostic significance , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[12]  Xin Huang,et al.  Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.

[13]  E. Lengyel,et al.  C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu , 2005, International journal of cancer.

[14]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[15]  G. Watkins,et al.  The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer , 2004, Clinical Cancer Research.

[16]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[17]  B. Zbar,et al.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.

[18]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[19]  K. Miyazaki,et al.  Expression of the hepatocyte growth factor/c‐Met pathway is increased at the cancer front in breast carcinoma , 2001, Pathology international.

[20]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[21]  T. Nakajima,et al.  Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance , 1996, Japanese journal of cancer research : Gann.

[22]  M. Ogawa,et al.  Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.

[23]  J. Bruix,et al.  c‐met mRNA overexpression in human hepatocellular carcinoma , 1994, Hepatology.

[24]  W. Birchmeier,et al.  Evidence for the identity of human scatter factor and human hepatocyte growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[26]  E. Gherardi,et al.  Hepatocytes and scatter factor , 1990, Nature.

[27]  K. Tashiro,et al.  Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.

[28]  M. Okigaki,et al.  Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. , 1989, Biochemical and biophysical research communications.

[29]  G. Michalopoulos,et al.  Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. , 1989, Cancer research.

[30]  Michael Stoker,et al.  Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.